Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases

By Drug Discovery Trends Editor | February 11, 2026

A new international collaboration backed by a pan-European EUREKA grant aims to develop targeted small-molecule therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD).

Evogene (Nasdaq: EVGN), Systasy Bioscience, and LMU University Hospital Munich announced the partnership on Feb. 11, with additional participation from the Weizmann Institute of Science. The program brings together AI-powered molecular design, iPSC-based functional profiling, and clinical expertise in rare immunodeficiencies to tackle what the partners describe as a significant unmet therapeutic need.

Neutrophils are among the first immune cells to respond to inflammation and are key drivers of tissue damage in a range of immune-mediated conditions. Yet the partners argue that current treatments do not directly and selectively target neutrophil-driven inflammation in these conditions, leaving a gap they aim to address.

The scientific rationale stems from work by Prof. Christoph Klein at LMU’s Dr. von Hauner Children’s Hospital. Klein’s group identified a rare genetic immunodeficiency associated with reduced neutrophil counts but without significant functional immune impairment. The collaboration aims to translate that naturally occurring biology into a therapeutic strategy. That is, modulating excessive neutrophil-driven inflammation while potentially avoiding the broad immune suppression typical of current treatments.

“We care for children with rare diseases every day; occasionally, we discover novel genetic defects and elucidate pathomechanisms,” Klein said. “Only rarely, however, is clinical and scientific knowledge translated into the development of novel therapeutic strategies.”

Each partner contributes distinct capabilities. Evogene will lead the small-molecule discovery effort using its ChemPass AI generative engine to design, optimize and prioritize novel inhibitors. The Weizmann Institute will support high-throughput experimental validation integrated with the computational design process. Systasy will extend its PathwayProfiler platform, built on proprietary DNA barcoding technology, to generate multiplexed functional data from stem cell-derived neutrophils. The goal is providing high-dimensional readouts to validate and refine AI-designed candidates. In adddition, LMU will validate lead compounds in human in vitro neutrophil models and support biomarker discovery and translational development.

“The support of the prestigious EUREKA grant is a strong vote of confidence in this synergistic collaboration, as well as further acknowledgment of the uniqueness of ChemPass AI,” said Ofer Haviv, Evogene’s president and CEO.

The announcement follows a productive stretch for Evogene’s pharma partnerships. In January, the company announced a collaboration with Unravel Biosciences to develop a small-molecule therapy for demyelinating disorder. This week also expanded its Google Cloud partnership to integrate AI agents into the ChemPass AI platform.

Hundreds of millions of people worldwide are affected by inflammatory and immune-mediated diseases in which neutrophils play a pathogenic role, according to the companies. Global IBD prevalence estimates vary by source and methodology; some widely cited analyses put the figure at roughly 6.8 million in 2017, with incidence rising in newly industrialized countries.

The EUREKA program, which supports market-oriented cross-border R&D projects, provided the funding framework for the collaboration. Financial terms were not disclosed.


Filed Under: Drug Discovery, machine learning and AI
Tagged With: AI drug discovery, biotech collaboration, ChemPass AI, Christoph Klein, EUREKA grant, Evogene, generative AI in pharma, IBD, immunology research, inflammatory bowel disease, LMU University Hospital Munich, neutrophil-driven inflammation, neutrophils, PathwayProfiler, rare immunodeficiencies, small-molecule therapies, stem cell-derived neutrophils, Systasy Bioscience, translational medicine, Weizmann Institute of Science
 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE